See the DrugPatentWatch profile for Jornay
Information regarding the marketing authorization status of Jornay PM in Europe is not readily available in the provided context.
When might Jornay PM be available in Europe?
The availability of Jornay PM in Europe depends on regulatory approvals from European health authorities. Without specific information on marketing authorization applications or approvals, it is not possible to determine a timeline for its market entry.
What is Jornay PM?
Jornay PM is a medication approved in the United States for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals 6 years of age and older. It is a novel extended-release formulation of methylphenidate, designed to be taken in the evening and to provide symptom control throughout the day [1]. The "PM" formulation is designed to release a dose of methylphenidate at bedtime, followed by a second release in the morning [1].
How does Jornay PM work for ADHD?
Jornay PM is a central nervous system stimulant that works by affecting the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine. These neurotransmitters play a role in attention, impulse control, and hyperactivity. By increasing the availability of these neurotransmitters, Jornay PM helps to improve focus and reduce impulsive behaviors and hyperactivity in individuals with ADHD [1].
What are the active ingredients in Jornay PM?
The active ingredient in Jornay PM is methylphenidate [1].
Are there similar ADHD medications available in Europe?
Numerous medications for ADHD are available in Europe, including various formulations of methylphenidate and amphetamines. However, the specific extended-release technology used in Jornay PM may differ from other available treatments.
Who manufactures Jornay PM?
Ironshore Pharmaceuticals developed Jornay PM.
What is the patent status of Jornay PM?
Information regarding specific patent protections for Jornay PM in Europe is not provided. DrugPatentWatch.com is a resource for exploring pharmaceutical patent information [2].
What clinical data supports Jornay PM's use?
Clinical trials have demonstrated the efficacy and safety of Jornay PM in treating ADHD symptoms in children and adolescents. Studies have shown improvements in ADHD symptoms from morning to evening. The most common side effects reported in clinical trials included decreased appetite, insomnia, and headache [1].
What are potential side effects of Jornay PM?
Common side effects of Jornay PM can include decreased appetite, insomnia, and headache. Serious side effects may include cardiovascular problems, psychiatric issues, and circulation problems. It is important to discuss any potential risks and side effects with a healthcare professional [1].
How is Jornay PM different from other methylphenidate formulations?
Jornay PM distinguishes itself through its novel extended-release delivery system, which allows for administration in the evening to provide symptom control throughout the following day. This differs from many other methylphenidate formulations that require morning dosing for daytime symptom management [1].
Sources:
[1] https://www.jornay.com/
[2] https://drugpatentwatch.com/